Pieris reports positive progress for asthma drug candidates
Pieris is developing a novel class of targeted human protein therapeutics called Anticalins. In studies of its proprietary PRS-060 Anticalin candidate, the company reports that the protein can
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.